KTTA•benzinga•
Pasithea Therapeutics' New Preclinical Data Shows PAS-004 Provides Superior Inhibition Of ETS2-Driven Inflammatory Responses Compared To Selumetinib In Human Macrophage Model Of Chronic Inflammation In IBD
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2025 by benzinga